Doctors studied over two thousand four hundred patients who had a stroke and were treated with clot-busting medicine. The review looked at three options: the standard drug, a newer drug called tenecteplase, and an even newer option called JX10. The main goal was to see which treatment helped the most people regain their ability to walk and live independently after ninety days.
The standard drug worked best for getting blood flowing again quickly. It also helped more patients recover their function compared to doing nothing or using a fake treatment. However, this standard drug also caused a much higher risk of serious bleeding inside the brain compared to usual care. The newer drugs showed some good signs of helping, but the data was not strong enough to say they were definitely better yet.
No study showed that one drug killed more people than the others. Because the evidence for the new options is not yet strong, doctors must carefully weigh the benefits against the risks. Each patient is different, so the best choice depends on their specific scan results and bleeding risk. More large studies are needed to prove if the new drugs are truly safe and effective before they are widely used.